Acumen Pharmaceuticals (Acumen Pharmaceuticals) Sloan Ratio % : 44.44% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Acumen Pharmaceuticals's Sloan Ratio for the quarter that ended in Mar. 2024 was 44.44%.

Warning Sign:

When sloan ratio (52.35)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Acumen Pharmaceuticals has a Sloan Ratio of 44.44%, indicating earnings are more likely to be made up of accruals.

Acumen Pharmaceuticals Sloan Ratio % Historical Data

The historical data trend for Acumen Pharmaceuticals's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acumen Pharmaceuticals Sloan Ratio % Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

9.32

-23.85

52.35

Acumen Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial													-5.52	-5.02	49.06	52.35	44.44

Competitive Comparison of Acumen Pharmaceuticals's Sloan Ratio %

For the Biotechnology subindustry, Acumen Pharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's Sloan Ratio % falls into.

Acumen Pharmaceuticals Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Acumen Pharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-52.371	-	-43.064
	-	-171.671)	/	310.125
	=	52.35%

Acumen Pharmaceuticals's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Mar. 2024 )
	=	(-55.937	-	-50.748
	-	-138.947)	/	300.967
	=	44.44%

Acumen Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -11.61 (Jun. 2023 ) + -12.957 (Sep. 2023 ) + -16.497 (Dec. 2023 ) + -14.873 (Mar. 2024 ) = $-55.94 Mil.
Acumen Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -11.67 (Jun. 2023 ) + -12.905 (Sep. 2023 ) + -8.314 (Dec. 2023 ) + -17.859 (Mar. 2024 ) = $-50.75 Mil.
Acumen Pharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 11.064 (Jun. 2023 ) + -92.001 (Sep. 2023 ) + -48.807 (Dec. 2023 ) + -9.203 (Mar. 2024 ) = $-138.95 Mil.

Acumen Pharmaceuticals (NAS:ABOS) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Acumen Pharmaceuticals has a Sloan Ratio of 44.44%, indicating earnings are more likely to be made up of accruals.

Acumen Pharmaceuticals Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

427 Park Street, Charlottesville, VA, USA, 22902

Website

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Executives

Daniel Joseph Oconnell	director, officer: President and CEO	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner	officer: Chief Legal Office & Corp Sec	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers	officer: Chief Medical Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton	officer: Chief Operating Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga	officer: Chief Financial Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p.	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209